TY - JOUR
T1 - Comparative accuracy of prognostic models for short-term mortality in acute-on-chronic liver failure patients
T2 - CAP-ACLF
AU - APASL ACLF Working Party
AU - Verma, Nipun
AU - Dhiman, Radha Krishan
AU - Singh, Virendra
AU - Duseja, Ajay
AU - Taneja, Sunil
AU - Choudhury, Ashok
AU - Sharma, Manoj Kumar
AU - Eapen, C. E.
AU - Devarbhavi, Harshad
AU - Al Mahtab, Mamun
AU - Shukla, Akash
AU - Hamid, Saeed Sadiq
AU - Jafri, Wasim
AU - Butt, Amna Shubhan
AU - Ning, Qin
AU - Chen, Tao
AU - Tan, Soek Siam
AU - Lesmana, Laurentius A.
AU - Lesmana, Cosmas Rinaldi A.
AU - Sahu, Manoj K.
AU - Hu, Jinhua
AU - Lee, Guan Huei
AU - Sood, Ajit
AU - Midha, Vandana
AU - Goyal, Omesh
AU - Ghazinian, Hasmik
AU - Kim, Dong Joon
AU - Treeprasertsuk, Sombat
AU - Mohan Prasad, V. G.
AU - Dokmeci, Abdul Kadir
AU - Sollano, Jose D.
AU - Shah, Samir
AU - Payawal, Diana Alcantara
AU - Rao, P. N.
AU - Kulkarni, Anand
AU - Lau, George K.
AU - Duan, Zhongping
AU - Chen, Yu
AU - Yokosuka, Osamu
AU - Abbas, Zaigham
AU - Karim, Fazal
AU - Chowdhury, Debashish
AU - Prasad, Ananta Shrestha
AU - Sarin, Shiv Kumar
N1 - Funding Information:
This work was presented as an oral presentation at the 29th Asian Pacific Association for the Study of the Liver (APASL) 2020 in Bali, Indonesia.
Publisher Copyright:
© 2021, Asian Pacific Association for the Study of the Liver.
PY - 2021/6
Y1 - 2021/6
N2 - Background: Multiple predictive models of mortality exist for acute-on-chronic liver failure (ACLF) patients that often create confusion during decision-making. We studied the natural history and evaluated the performance of prognostic models in ACLF patients. Methods: Prospectively collected data of ACLF patients from APASL-ACLF Research Consortium (AARC) was analyzed for 30-day outcomes. The models evaluated at days 0, 4, and 7 of presentation for 30-day mortality were: AARC (model and score), CLIF-C (ACLF score, and OF score), NACSELD-ACLF (model and binary), SOFA, APACHE-II, MELD, MELD-Lactate, and CTP. Evaluation parameters were discrimination (c-indices), calibration [accuracy, sensitivity, specificity, and positive/negative predictive values (PPV/NPV)], Akaike/Bayesian Information Criteria (AIC/BIC), Nagelkerke-R2, relative prediction errors, and odds ratios. Results: Thirty-day survival of the cohort (n = 2864) was 64.9% and was lowest for final-AARC-grade-III (32.8%) ACLF. Performance parameters of all models were best at day 7 than at day 4 or day 0 (p < 0.05 for C-indices of all models except NACSELD-ACLF). On comparison, day-7 AARC model had the numerically highest c-index 0.872, best accuracy 84.0%, PPV 87.8%, R2 0.609 and lower prediction errors by 10–50%. Day-7 NACSELD-ACLF-binary was the simple model (minimum AIC/BIC 12/17) with the highest odds (8.859) and sensitivity (100%) but with a lower PPV (70%) for mortality. Patients with day-7 AARC score > 12 had the lowest 30-day survival (5.7%). Conclusions: APASL-ACLF is often a progressive disease, and models assessed up to day 7 of presentation reliably predict 30-day mortality. Day-7 AARC model is a statistically robust tool for classifying risk of death and accurately predicting 30-day outcomes with relatively lower prediction errors. Day-7 AARC score > 12 may be used as a futility criterion in APASL-ACLF patients.
AB - Background: Multiple predictive models of mortality exist for acute-on-chronic liver failure (ACLF) patients that often create confusion during decision-making. We studied the natural history and evaluated the performance of prognostic models in ACLF patients. Methods: Prospectively collected data of ACLF patients from APASL-ACLF Research Consortium (AARC) was analyzed for 30-day outcomes. The models evaluated at days 0, 4, and 7 of presentation for 30-day mortality were: AARC (model and score), CLIF-C (ACLF score, and OF score), NACSELD-ACLF (model and binary), SOFA, APACHE-II, MELD, MELD-Lactate, and CTP. Evaluation parameters were discrimination (c-indices), calibration [accuracy, sensitivity, specificity, and positive/negative predictive values (PPV/NPV)], Akaike/Bayesian Information Criteria (AIC/BIC), Nagelkerke-R2, relative prediction errors, and odds ratios. Results: Thirty-day survival of the cohort (n = 2864) was 64.9% and was lowest for final-AARC-grade-III (32.8%) ACLF. Performance parameters of all models were best at day 7 than at day 4 or day 0 (p < 0.05 for C-indices of all models except NACSELD-ACLF). On comparison, day-7 AARC model had the numerically highest c-index 0.872, best accuracy 84.0%, PPV 87.8%, R2 0.609 and lower prediction errors by 10–50%. Day-7 NACSELD-ACLF-binary was the simple model (minimum AIC/BIC 12/17) with the highest odds (8.859) and sensitivity (100%) but with a lower PPV (70%) for mortality. Patients with day-7 AARC score > 12 had the lowest 30-day survival (5.7%). Conclusions: APASL-ACLF is often a progressive disease, and models assessed up to day 7 of presentation reliably predict 30-day mortality. Day-7 AARC model is a statistically robust tool for classifying risk of death and accurately predicting 30-day outcomes with relatively lower prediction errors. Day-7 AARC score > 12 may be used as a futility criterion in APASL-ACLF patients.
KW - AARC
KW - APASL
KW - CILF-C ACLF
KW - Deaths
KW - EASL
KW - Liver failure
KW - MELD
KW - NACSELD
KW - Natural history
KW - Prediction
UR - http://www.scopus.com/inward/record.url?scp=85109000124&partnerID=8YFLogxK
U2 - 10.1007/s12072-021-10175-w
DO - 10.1007/s12072-021-10175-w
M3 - Article
C2 - 34173167
AN - SCOPUS:85109000124
SN - 1936-0533
VL - 15
SP - 753
EP - 765
JO - Hepatology International
JF - Hepatology International
IS - 3
ER -